Nautilus Biotechnology Inc’s filing revealed that its Chief Scientist Mallick Parag acquired Company’s shares for reported $8788.0 on May 08 ’25. In the deal valued at $0.73 per share,12,000 shares were bought. As a result of this transaction, Mallick Parag now holds 20,491,892 shares worth roughly $19.06 million.
Then, Mallick Parag bought 1,500 shares, generating $1,098 in total proceeds. Upon buying the shares at $0.73, the Chief Scientist now owns 20,493,392 shares.
Before that, Patel Sujal M bought 53,300 shares. Nautilus Biotechnology Inc shares valued at $53,028 were divested by the CEO, President, and Secretary at a price of $0.99 per share. As a result of the transaction, Patel Sujal M now holds 10,117,788 shares, worth roughly $9.41 million.
Goldman downgraded its Nautilus Biotechnology Inc [NAUT] rating to a Sell from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. Morgan Stanley started covering the stock on January 06, 2022. It rated NAUT as “an Equal-weight”.
Price Performance Review of NAUT
On Tuesday, Nautilus Biotechnology Inc [NASDAQ:NAUT] saw its stock jump 28.22% to $0.93. Over the last five days, the stock has gained 38.79%. Nautilus Biotechnology Inc shares have fallen nearly -44.82% since the year began. Nevertheless, the stocks have fallen -66.89% over the past one year. While a 52-week high of $3.09 was reached on 01/21/25, a 52-week low of $0.66 was recorded on 05/05/25. SMA at 50 days reached $0.8651, while 200 days put it at $1.9233.
Levels Of Support And Resistance For NAUT Stock
The 24-hour chart illustrates a support level at 0.7744, which if violated will result in even more drops to 0.6218. On the upside, there is a resistance level at 1.0448. A further resistance level may holdings at 1.1626. The Relative Strength Index (RSI) on the 14-day chart is 62.82, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0702, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 23.71%. Stochastics %K at 46.60% indicates the stock is a holding.
The most recent change occurred on November 02, 2021 when Cowen began covering the stock and recommended ‘”an Outperform”‘ rating .
